Literature DB >> 11920858

Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects.

Tao Li1, Xiehe Liu, Jinghua Zhao, Xun Hu, David M Ball, El-Wui Loh, Pak C Sham, David A Collier.   

Abstract

Five candidate genes, the receptors DRD2, DRD3, HTR2A and GABA(A)gamma2, and the serotonin transporter (5-HTT) were analyzed for association with heroin abuse. We examined three polymorphisms (promoter - 141DeltaC, Ser311Cys, and TaqI) in the DRD2 gene, one polymorphism (Ser9Gly) in the DRD3 gene, two polymorphisms (promoter - 1438G/A and T102C) in the HTR2A gene, two polymorphisms (VNTR and Del/Ins) in 5-HTT gene, and one polymorphism (G3145A) in GABA(A)gamma2 gene in 121 Chinese heroin addicts and 194 controls. None of the polymorphisms differed significantly for allele, genotype, or haplotype frequencies, except for the DRD2 promoter polymorphism - 141DeltaC (genotype-wise and allele-wise, P = 0.05, uncorrected). An additional 344 subjects with heroin abuse and 104 controls were investigated for the - 141DeltaC polymorphism. In the second sample, there were no significant difference of genotype or allele frequencies between subjects with heroin abuse and normal controls. When we divided the sample by route of administration into nasal inhalers and IM or IV injectors, however, it produced a significant difference between inhalers of heroin and controls (genotype-wise, P = 0.006, allele-wise, P = 0.016) but not for injectors of heroin (genotype-wise, P = 0.81, allele-wise, P = 0.69). We also found that LD between all polymorphisms we examined in the gene was weak, possibly explaining why we see association of this polymorphism with heroin abuse but not with other markers in the gene. Overall our results indicates that the HTR2A, 5-HTT, DRD3 and GABA(A)gamma2 genes are not likely to be a major genetic risk factor for heroin abuse in this population, with the exception of possible association between nasal inhalation and DRD2 promoter - 141DeltaC polymorphism. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920858     DOI: 10.1002/ajmg.10200

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  22 in total

1.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

Review 2.  From dopaminergic genes to psychiatric disorders.

Authors:  Janet Hoenicka; María Aragüés; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel A Jiménez-Arriero; Tomás Palomo
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 3.  An overview of the genetics of substance use disorders.

Authors:  H M Lachman
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

4.  Genotype patterns that contribute to increased risk for or protection from developing heroin addiction.

Authors:  D A Nielsen; F Ji; V Yuferov; A Ho; A Chen; O Levran; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2008-01-15       Impact factor: 15.992

5.  Association of the HTR2A gene with alcohol and heroin abuse.

Authors:  Jian Cao; Xiangtao Liu; Shizhong Han; Clarence K Zhang; Zongzhi Liu; Dawei Li
Journal:  Hum Genet       Date:  2013-11-01       Impact factor: 4.132

Review 6.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

7.  Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

8.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

9.  Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels.

Authors:  M M Jacobs; A Ökvist; M Horvath; E Keller; M J Bannon; S Morgello; Y L Hurd
Journal:  Mol Psychiatry       Date:  2012-10-09       Impact factor: 15.992

10.  ADHD risk alleles associated with opiate addiction: study of addicted parents and their children.

Authors:  Asher Ornoy; Victoria Finkel-Pekarsky; Einat Peles; Miriam Adelson; Shaul Schreiber; P Richard Ebstein
Journal:  Pediatr Res       Date:  2016-04-11       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.